Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18799447 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18416981 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18504029 | INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID | November 2023 | April 2024 | Abandon | 5 | 0 | 1 | Yes | No |
| 17736148 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | May 2022 | February 2023 | Allow | 9 | 1 | 0 | No | No |
| 17571193 | RNAi Insecticide Materials and Methods | January 2022 | February 2025 | Allow | 37 | 0 | 0 | No | No |
| 17554274 | NXTAR-DERIVED OLIGONUCLEOTIDES AND USES THEREOF | December 2021 | August 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17527953 | MODULATORS OF YAP1 EXPRESSION | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17520530 | Methods and Compositions for Selecting siRNA of Improved Functionality | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17387495 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | July 2021 | January 2025 | Allow | 42 | 1 | 0 | No | No |
| 17384417 | Stabilized CRISPR Complexes | July 2021 | May 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17380756 | TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS | July 2021 | September 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17422118 | GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENE | July 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17367242 | TAU ANTISENSE OLIGOMERS AND USES THEREOF | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17364618 | ANTISENSE NUCLEIC ACIDS | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17416735 | DNA APTAMERS SPECIFIC OF ADENOVIRUS TYPES | June 2021 | February 2025 | Allow | 44 | 1 | 0 | No | No |
| 17352716 | BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES | June 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17413550 | DNA APTAMERS AND USE THEREOF FOR THE TREATMENT OF CANCER | June 2021 | May 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17345624 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | June 2021 | June 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17245735 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | April 2021 | December 2021 | Allow | 7 | 1 | 0 | No | No |
| 17244272 | ANTIVIRAL AGENTS FOR TREATMENT OF CORONAVIRUSES | April 2021 | June 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17238612 | USING MICRORNAS TO CONTROL ACTIVATION STATUS OF HEPATIC STELLATE CELLS AND TO PREVENT FIBROSIS IN PROGRESSIVE LIVER DISEASES | April 2021 | April 2025 | Allow | 48 | 2 | 0 | No | No |
| 17236851 | MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCER | April 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
| 17205102 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | March 2021 | January 2024 | Allow | 34 | 4 | 0 | Yes | Yes |
| 17200146 | GFI1 INHIBITORS FOR THE TREATMENT OF HYPERGLYCEMIA | March 2021 | May 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17178846 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17177111 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | February 2021 | April 2025 | Allow | 50 | 0 | 1 | No | No |
| 17168709 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | February 2021 | April 2025 | Abandon | 50 | 3 | 0 | No | No |
| 17266556 | COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS | February 2021 | April 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17159586 | Use of Trinucleotide Repeat RNAs To Treat Cancer | January 2021 | December 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17131130 | RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy | December 2020 | October 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17108450 | ANTI-ARID3A TREATMENTS FOR INFLAMMATORY DISORDERS | December 2020 | May 2025 | Abandon | 54 | 2 | 0 | No | No |
| 17106259 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17056233 | Drug-Resistant Immune Cells and Methods of Use Thereof | November 2020 | February 2025 | Allow | 51 | 2 | 1 | No | No |
| 17053713 | Applications of Streptococcus-derived Cas9 nucleases on minimal Adenine-rich PAM targets | November 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17048227 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | October 2020 | February 2025 | Allow | 52 | 1 | 1 | No | No |
| 17047271 | NOVEL SUBSTITUTED RIG-I AGONISTS: COMPOSITIONS AND METHODS THEREOF | October 2020 | August 2022 | Allow | 22 | 2 | 0 | No | No |
| 17033313 | SEQUENCE-SPECIFIC IN VIVO CELL TARGETING | September 2020 | March 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 16947905 | INHIBITION OF MIR-22 MIRNA BY APT-110 | August 2020 | January 2025 | Allow | 53 | 2 | 0 | No | No |
| 16999506 | Direct and Selective Inhibition of MDM4 for Treatment of Cancer | August 2020 | June 2024 | Allow | 46 | 2 | 0 | No | No |
| 16999695 | ANTISENSE NUCLEIC ACIDS | August 2020 | August 2024 | Allow | 48 | 1 | 1 | No | No |
| 16999051 | Methods and Compositions for Preventing or Treating Heart Disease | August 2020 | May 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16987050 | Read Through Of Truncated Proteins In Premature Termination Codon Diseases Using An Optimized Genetic Codon Expansion System | August 2020 | October 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16984887 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | August 2020 | December 2021 | Allow | 16 | 0 | 0 | No | No |
| 16936060 | MODULATORS OF PNPLA3 EXPRESSION | July 2020 | May 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16927452 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | July 2020 | June 2022 | Abandon | 23 | 2 | 0 | No | No |
| 16957249 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY METASTASIS OF CANCER INCLUDING CHI3L1 INHIBITOR AS ACTIVE INGREDIENT | June 2020 | July 2022 | Allow | 25 | 1 | 0 | No | No |
| 16956827 | DNA ORIGAMI NANOPARTICLE DELIVERY OF PROGRAMMED CHROMOSOME BREAKAGE MACHINERY | June 2020 | September 2024 | Abandon | 51 | 3 | 1 | No | No |
| 15733307 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | June 2020 | May 2024 | Abandon | 47 | 4 | 0 | No | No |
| 16884782 | MODULATORS OF GROWTH HORMONE RECEPTOR | May 2020 | June 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16872051 | MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS | May 2020 | June 2021 | Allow | 14 | 2 | 1 | No | No |
| 16867925 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | May 2020 | September 2024 | Abandon | 53 | 4 | 1 | Yes | No |
| 16851689 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | April 2020 | October 2022 | Abandon | 30 | 2 | 0 | No | Yes |
| 16847499 | PREECLAMPSIA | April 2020 | February 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16812714 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | March 2020 | April 2024 | Allow | 51 | 3 | 1 | No | Yes |
| 16811476 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | March 2020 | January 2021 | Abandon | 10 | 1 | 0 | No | No |
| 16645083 | COMPOSITIONS AND METHODS FOR TREATING TRANSPOSON ASSOCIATED DISEASES | March 2020 | January 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16806941 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | March 2020 | January 2022 | Abandon | 22 | 3 | 0 | No | No |
| 16802014 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | February 2020 | February 2022 | Allow | 24 | 1 | 0 | No | No |
| 16782976 | Methods and Compositions for Selecting siRNA of Improved Functionality | February 2020 | August 2021 | Allow | 18 | 1 | 1 | No | No |
| 16778949 | MODULATORS OF YAP1 EXPRESSION | January 2020 | August 2021 | Allow | 19 | 1 | 0 | No | No |
| 16777214 | THERAPEUTIC SPLICE-SWITCHING OLIGONUCLEOTIDES | January 2020 | April 2022 | Allow | 27 | 5 | 0 | Yes | No |
| 16774910 | ANTICANCER THERAPEUTIC INTERVENTION | January 2020 | December 2021 | Allow | 23 | 3 | 1 | Yes | No |
| 16631995 | NUCLEIC ACID SIMULTANEOUSLY INHIBITING EXPRESSION OF AR GENE AND MTOR GENE | January 2020 | November 2020 | Allow | 10 | 1 | 0 | Yes | No |
| 16628811 | METHODS FOR TREATING INFLAMMATION AND RELATED DISEASES AND DISORDERS BY INHIBITING ALPHA PROTEIN KINASE 1 | January 2020 | September 2024 | Abandon | 56 | 5 | 1 | No | No |
| 16732740 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE ENDURANCE, PERFORMANCE, OR TOLERANCE | January 2020 | June 2021 | Abandon | 18 | 5 | 0 | Yes | No |
| 16501000 | FUNCTION INHIBITOR OF SWI/SNF COMPLEXES | December 2019 | January 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16716705 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2019 | December 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16710144 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | December 2019 | June 2021 | Abandon | 18 | 2 | 0 | No | No |
| 16617631 | TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES | November 2019 | November 2024 | Abandon | 60 | 4 | 2 | No | No |
| 16617743 | NUCLEIC ACID SUPPRESSING EXPRESSION OF APCS | November 2019 | May 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16617431 | THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III | November 2019 | April 2022 | Allow | 29 | 0 | 1 | Yes | No |
| 16614644 | COMPOSITION FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 36 | November 2019 | August 2021 | Allow | 21 | 3 | 0 | No | No |
| 16680340 | siRNA Targeting LDHA | November 2019 | October 2020 | Abandon | 11 | 1 | 0 | No | No |
| 16678600 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | November 2019 | April 2020 | Allow | 5 | 1 | 0 | Yes | No |
| 16612313 | NEW THERAPY | November 2019 | June 2023 | Allow | 43 | 3 | 0 | No | No |
| 16611046 | MODULATORY POLYNUCLEOTIDES | November 2019 | January 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16664527 | Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1) | October 2019 | October 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16660986 | TREATMENT STRATEGIES AGAINST ANTHRAX BY INTERFERING WITH CRITICAL HOST FACTORS | October 2019 | November 2023 | Allow | 49 | 8 | 1 | Yes | No |
| 16606236 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION | October 2019 | May 2022 | Allow | 31 | 2 | 0 | Yes | No |
| 16596553 | METHOD OF MANUFACTURING VESICLES BY DELIVERY OF RNA NANOPARTICLES AND VESICLES MANUFACTURED USING THE SAME | October 2019 | January 2024 | Abandon | 52 | 4 | 0 | Yes | No |
| 16498408 | REGULATION OF MIR-143 USING NUCLEIC ACID MOLECULES | September 2019 | August 2023 | Allow | 46 | 6 | 1 | Yes | Yes |
| 16496720 | VECTORS AND COMPOSITIONS FOR TREATING HEMOGLOBINOPATHIES | September 2019 | October 2021 | Allow | 25 | 4 | 0 | Yes | No |
| 16496761 | GFI1 INHIBITORS FOR THE TREATMENT OF HYPERGLYCEMIA | September 2019 | December 2020 | Allow | 15 | 2 | 0 | No | No |
| 16495555 | METHOD FOR PREDICTION OF SUSCEPTIBILITY TO SORAFENIB TREATMENT BY USING SULF2 GENE, AND COMPOSITION FOR TREATMENT OF CANCER COMPRISING SULF2 INHIBITOR | September 2019 | July 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16574407 | MODULATORS OF PNPLA3 EXPRESSION | September 2019 | May 2020 | Allow | 8 | 0 | 0 | No | No |
| 16572234 | HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLS | September 2019 | March 2024 | Allow | 54 | 3 | 1 | No | No |
| 16559568 | TREATMENT OF ALZHEIMERS DISEASE WITH MICRO RNA AND GHRELIN | September 2019 | July 2023 | Abandon | 46 | 3 | 0 | Yes | No |
| 16554115 | Compositions for Modulating Expression of C9ORF72 Antisense Transcript | August 2019 | August 2021 | Allow | 24 | 2 | 0 | No | No |
| 16551847 | RNAI STRATEGIES FOR CONTROL OF WHITEFLY | August 2019 | April 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16487587 | REGULATION OF GENE EXPRESSION BY APTAMER-MODULATED RNASE P CLEAVAGE | August 2019 | April 2023 | Allow | 44 | 2 | 0 | No | No |
| 16487223 | Regulation of Gene Expression by Aptamer-Mediated Accessibility of Polyadenylation Signals | August 2019 | May 2023 | Abandon | 45 | 2 | 0 | No | No |
| 16487377 | SYSTEM AND METHOD FOR CELL TYPE-SPECIFIC TRANSLATION OF RNA MOLECULES IN EUKARYOTES | August 2019 | April 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16540973 | METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION | August 2019 | October 2021 | Allow | 26 | 2 | 1 | Yes | No |
| 16530600 | Molecular Recognition Systems with Pyrimidine Analog Pairing | August 2019 | July 2020 | Allow | 11 | 1 | 0 | No | No |
| 16483012 | POLYNUCLEOTIDE SECONDARY STRUCTURE | August 2019 | January 2023 | Abandon | 41 | 3 | 1 | No | Yes |
| 16521344 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | July 2019 | April 2020 | Allow | 9 | 1 | 0 | No | No |
| 16477656 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION | July 2019 | February 2021 | Abandon | 19 | 1 | 1 | No | No |
| 16475275 | NUCLEIC ACIDS AND METHODS FOR GENOME EDITING | July 2019 | February 2024 | Abandon | 55 | 1 | 0 | No | No |
| 16474776 | ENDOSOMAL CLEAVABLE LINKERS | June 2019 | November 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16449093 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | June 2019 | January 2022 | Allow | 31 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHNIZER, RICHARD A.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHNIZER, RICHARD A works in Art Unit 1635 and has examined 896 patent applications in our dataset. With an allowance rate of 45.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner SCHNIZER, RICHARD A's allowance rate of 45.4% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHNIZER, RICHARD A receive 2.20 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SCHNIZER, RICHARD A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +36.3% benefit to allowance rate for applications examined by SCHNIZER, RICHARD A. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.4% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.2% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 87.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 12.6% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.9% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.